SHP648
/ Takeda
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
July 01, 2021
A Phase 1/2 Study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B Subjects
(clinicaltrials.gov)
- P1/2; N=2; Terminated; Sponsor: Baxalta now part of Shire; No subjects have been dosed with SHP648. The decision to terminate study SHP648-101 is not due to any safety concerns.
Clinical • Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Gene Therapies • Hematological Disorders • Hemophilia • Rare Diseases
September 14, 2020
A Phase 1/2 Study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B Subjects
(clinicaltrials.gov)
- P1/2; N=21; Suspended; Sponsor: Baxalta now part of Shire; Recruiting ➔ Suspended
Clinical • Trial suspension • Gene Therapies • Hematological Disorders • Hemophilia • Rare Diseases
May 19, 2020
A Phase 1/2 Study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B Subjects
(clinicaltrials.gov)
- P1/2; N=21; Recruiting; Sponsor: Baxalta now part of Shire
Clinical • New P1/2 trial • Gene Therapies • Hematological Disorders • Hemophilia • Rare Diseases
1 to 3
Of
3
Go to page
1